Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. Now, the biotech has distanced itself from its premerger form by ...

Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets Company ...

(RTTNews) - Aileron Therapeutics, Inc.(ALRN) a Boston-based biopharmaceutical company Friday has announced that it has rebranded itself into Rein Therapeutics, Inc. The updated name, logo ...

Aileron Therapeutics ( (ALRN)) has released its Q3 earnings. Here is a breakdown of the information Aileron Therapeutics presented to its investors. Aileron Therapeutics, Inc. is a clinical-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AUSTIN, Texas, Jan. 10, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a ...

Rein Therapeutics (RNTX), formerly known as Aileron Therapeutics (ALRN), has changed its name to Rein Therapeutics. The new name, logo, website, and branding elements reflect the Company’s ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX ), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN ), a biopharmaceutical company advancing a novel ...

"Our rebrand to Rein Therapeutics reflects our unwavering commitment to address the critical needs of underserved patients with fibrotic diseases," said Brian Windsor, Ph.D., President and Chief ...